Valuation: Immatics N.V.

Market Cap 1.04B 922M 860M 784M 1.48B 99.74B 1.49B 10.41B 4.03B 50.99B 3.9B 3.81B 164B P/E 2026 *
-3.59x
P/E 2027 * -3.61x
Enterprise Value 751M 668M 623M 568M 1.07B 72.22B 1.08B 7.54B 2.92B 36.92B 2.82B 2.76B 118B EV / Sales 2026 *
16.1x
EV / Sales 2027 * 17.7x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day-10.07%
1 week-9.32%
Current month-13.55%
1 month-20.11%
3 months-23.72%
6 months-26.67%
Current year-27.71%
1 week 7.4
Extreme 7.4
9.16
1 month 7.4
Extreme 7.4
9.57
Current year 7.4
Extreme 7.4
11.94
1 year 7.4
Extreme 7.4
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14.9
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 2018-12-31
Director of Finance/CFO 57 2025-09-30
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 51 2020-06-30
Chairman 70 2012-09-30
Director/Board Member 72 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
3/18/26 Other

Chief Financial Officer

350,000 0.2611%
3/18/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-10.07%-9.32%-13.06%-29.66% 1.04B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -1.21%-1.46%+47.64%+105.29% 39.16B
Weighted average by Cap. +0.09%-0.86%+58.57%+129.49%

Financials

2026 *2027 *
Net sales 46.54M 41.35M 38.59M 35.18M 66.34M 4.47B 66.96M 467M 181M 2.29B 175M 171M 7.34B 39.58M 35.17M 32.82M 29.92M 56.42M 3.81B 56.95M 397M 154M 1.95B 149M 145M 6.24B
Net income -287M -255M -238M -217M -410M -27.63B -414M -2.88B -1.12B -14.12B -1.08B -1.06B -45.33B -310M -275M -257M -234M -441M -29.77B -446M -3.11B -1.2B -15.22B -1.16B -1.14B -48.84B
Net Debt -286M -254M -237M -216M -408M -27.51B -412M -2.87B -1.11B -14.06B -1.07B -1.05B -45.14B -339M -301M -281M -256M -483M -32.56B -487M -3.4B -1.32B -16.65B -1.27B -1.24B -53.42B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
26-10-02 US$7.590 -10.07% 1,256,980
26-10-01 US$8.440 -3.87% 639,726
26-09-30 US$8.780 +2.57% 1,898,932
26-09-29 US$8.560 +0.71% 644,378
26-09-28 US$8.500 +1.55% 1,467,544
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.590USD
Average target price
17.63USD
Spread / Average Target
+132.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock